ALK and non-small cell lung carcinoma: ALK fusion partners are identified as driver events in nearly twenty different human malignancies, including non-small cell lung cancers (NSCLC), anaplastic non-Hodgkin lymphoma, diffuse large B cell lymphoma, renal carcinoma, thyroid cancers, breast cancer, ovarian carcinoma, leukemia, and MM6–8.